Recombinant human serum albumin (OsrHSA) has emerged as a significant innovation in the sector of biopharmaceuticals, supplying promising progress across several health-related and industrial purposes. With its structural similarity to Normally derived human serum albumin, OsrHSA presents a safer, far more responsible substitute for therapeutic use